These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 21846853)

  • 41. Recombinant human thyroid stimulating hormone-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence.
    Hugo J; Robenshtok E; Grewal R; Larson S; Tuttle RM
    Thyroid; 2012 Oct; 22(10):1007-15. PubMed ID: 22873801
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Energy level and fatigue after surgery for thyroid cancer: A population-based study of patient-reported outcomes.
    Hughes DT; Reyes-Gastelum D; Kovatch KJ; Hamilton AS; Ward KC; Haymart MR
    Surgery; 2020 Jan; 167(1):102-109. PubMed ID: 31582311
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Papillary thyroid cancer: factors involved in restaging N1 disease after total thyroidectomy and radioactive iodine treatment.
    Guy A; Hirsch D; Shohat T; Bachar G; Tirosh A; Robenshtok E; Shimon I; Benbassat CA
    J Clin Endocrinol Metab; 2014 Nov; 99(11):4167-73. PubMed ID: 25157544
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The impact of iodinated contrast agent administered during preoperative computed tomography scan on body iodine pool in patients with differentiated thyroid cancer preparing for radioactive iodine treatment.
    Sohn SY; Choi JH; Kim NK; Joung JY; Cho YY; Park SM; Kim TH; Jin SM; Bae JC; Lee SY; Chung JH; Kim SW
    Thyroid; 2014 May; 24(5):872-7. PubMed ID: 24295076
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CONCORDANCE OF PRE-OPERATIVE CLINICAL STAGE WITH PATHOLOGIC STAGE IN PATIENTS ≥45 YEARS OLD WITH WELL-DIFFERENTIATED THYROID CANCER.
    Calcatera NA; Lutfi W; Suman P; Suss NR; Wang CH; Prinz RA; Winchester DJ; Moo-Young TA
    Endocr Pract; 2018 Jan; 24(1):27-32. PubMed ID: 29144811
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Radioactive Iodine for Papillary Thyroid Carcinoma.
    Chan WWL; Kwong DLW
    Methods Mol Biol; 2022; 2534():225-241. PubMed ID: 35670979
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An impact of microscopic positive margin on incomplete response after I-131 treatment in differentiated thyroid cancer.
    Raruenrom Y; Sawangsri K; Somboonporn C; Theerakulpisut D; Wongsurawat N; Ratanaanekchai T
    Ann Nucl Med; 2020 Jul; 34(7):453-459. PubMed ID: 32323257
    [TBL] [Abstract][Full Text] [Related]  

  • 48. RISK FACTORS FOR NONREMISSION AND PROGRESSION-FREE SURVIVAL AFTER I-131 THERAPY IN PATIENTS WITH LUNG METASTASIS FROM DIFFERENTIATED THYROID CANCER: A SINGLE-INSTITUTE, RETROSPECTIVE ANALYSIS IN SOUTHERN CHINA.
    Chen P; Feng HJ; Ouyang W; Wu JQ; Wang J; Sun YG; Xian JL; Huang LH
    Endocr Pract; 2016 Sep; 22(9):1048-56. PubMed ID: 27124694
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison between the different doses of radioactive iodine ablation prescribed in patients with intermediate-to-high-risk differentiated thyroid cancer.
    Iizuka Y; Katagiri T; Ogura K; Mizowaki T
    Ann Nucl Med; 2019 Jul; 33(7):495-501. PubMed ID: 30955202
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Oncocytic Papillary Thyroid Carcinoma and Oncocytic Poorly Differentiated Thyroid Carcinoma: Clinical Features, Uptake, and Response to Radioactive Iodine Therapy, and Outcome.
    Lukovic J; Petrovic I; Liu Z; Armstrong SM; Brierley JD; Tsang R; Pasternak JD; Gomez-Hernandez K; Liu A; Asa SL; Mete O
    Front Endocrinol (Lausanne); 2021; 12():795184. PubMed ID: 34975765
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer.
    Ruel E; Thomas S; Dinan M; Perkins JM; Roman SA; Sosa JA
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1529-36. PubMed ID: 25642591
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Surgical approach and radioactive iodine therapy for small well-differentiated thyroid cancer.
    Momesso DP; Vaisman F; Caminha LS; Pessoa CH; Corbo R; Vaisman M
    J Endocrinol Invest; 2014 Jan; 37(1):57-64. PubMed ID: 24464451
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Differentiated Thyroid Cancer lymph-node relapse. Role of adjuvant radioactive iodine therapy after lymphadenectomy.
    Piccardo A; Puntoni M; Bottoni G; Treglia G; Foppiani L; Bertoli M; Catrambone U; Arlandini A; Dib B; Altrinetti V; Massollo M; Bossert I; Cabria M; Bertagna F; Giovanella L
    Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):926-934. PubMed ID: 27966046
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The efficacy of radioactive iodine for the treatment of well-differentiated thyroid cancer with distant metastasis.
    Lin JD; Kuo SF; Huang BY; Lin SF; Chen ST
    Nucl Med Commun; 2018 Dec; 39(12):1091-1096. PubMed ID: 30180044
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Factors influencing radioiodine uptake after thyroid cancer surgery.
    Bai JB; Shakerian R; Westcott JD; Lichtenstein M; Miller JA
    ANZ J Surg; 2015; 85(7-8):572-7. PubMed ID: 23964714
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Unexpected radioactive iodine accumulation on whole-body scan after I-131 ablation therapy for differentiated thyroid cancer.
    Iwano S; Ito S; Kamiya S; Ito R; Kato K; Naganawa S
    Nagoya J Med Sci; 2020 May; 82(2):205-215. PubMed ID: 32581401
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Optimal Timing of Initiating Dynamic Risk Stratification During the Early Postoperative Period in Patients with Differentiated Thyroid Carcinoma After Thyroidectomy and Radioactive Iodine Remnant Ablation.
    Park JH; Moon GS; Nam KT; Yoon JH
    Ann Surg Oncol; 2021 Oct; 28(11):6580-6589. PubMed ID: 33677764
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of Waiting Time for Radioactive Iodine Therapy on Outcome in N1 Stage Papillary Thyroid Cancer.
    Sun Y; Sun Q; Tian J; He X
    J Clin Endocrinol Metab; 2023 Oct; 108(11):e1413-e1423. PubMed ID: 37167097
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Short-term bone marrow suppression in differentiated thyroid cancer patients after radioactive iodine treatment.
    Yi W; Kim BH; Kim M; Ryang SR; Jang MH; Kim JM; Kim EH; Jeon YK; Kim SS; Kim IJ
    Endocr J; 2020 Dec; 67(12):1193-1198. PubMed ID: 32727965
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Do Lower-Risk Thyroid Cancer Patients Who Live in Regions with More Aggressive Treatments Have Better Outcomes?
    Hall SF; Irish J; Groome P; Griffiths R; Hurlbut D
    Thyroid; 2017 Oct; 27(10):1246-1257. PubMed ID: 28851261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.